The undelying mechanism may be that they can attenuate the resistance of cisplatin in lung cancer by inhibiting Akt and NF-KB, resuming immunity, and regulating DNA damage in NSCLC cells by activating the VRK1/P53BP1 pathway (Jiang et al., 2017; Liu T et al., 2019). Here, TP53BP1 is linked to non-small cell lung carcinoma.